Results 211 to 220 of about 17,826,638 (304)

Studying Chronic Lymphocytic Leukemia Microenvironment in the Multi Omics Era. [PDF]

Hematol Oncol
Bucci A, Notarpietro G, Apollonio B, Vegliante MC, Pappagallo SA, Mondelli P, Scattone A, Donati B, Ponzoni M, Frenquelli M, Ghia P, Minoia C.   +11 more
europepmc   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Concurrent Kaposi Sarcoma and B-cell Lymphoma in an HIV-Negative Patient: A Case Report. [PDF]

Cureus
Faik Ouahab M, El Ghouti B, Chiheb S, Eljazouly M.   +3 more
europepmc   +1 more source

Thermodynamic characterisation of covalent ligand binding

British Journal of Pharmacology, EarlyView.
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman, Maayan Lavie, Almog Nadir, Ronen Gabizon, Nir London   +4 more
wiley   +1 more source

TRAF1 S146 is constitutively phosphorylated in OP9-cultured primary chronic lymphocytic leukemia cells by PKN1/2. [PDF]

Immunohorizons
Ghumman B, Nicolucci L, Minden MD, Watts TH, Abdul-Sater AA.   +4 more
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System. [PDF]

Case Rep Hematol
D'Amato M, Baratè C, Cervetti G, Caparello M, Ortenzi V, Naccarato AG, Benedetti E, Galimberti S.   +7 more
europepmc   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

British Journal of Haematology, EarlyView.
Isacco Ferrarini, Daniela Estefania Banegas, Andrea Bernardelli, Alessia Moioli, Francesca Maria Quaglia, Ester Lovato, Anna Maria Frustaci, Massimiliano Postorino, Davide Facchinelli, Monica Tani, Francesca Cibien, Chandrakala Toldo, Elisa Lucchini, Roberto Marasca, Marzia Varettoni, Chiara Rusconi, Lucia Farina, Andrea Visentin, Riccardo Moia, Carlo Visco   +19 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

A 13-Year Review of Non-Diffuse Large B Cell Lymphomas of the Central Nervous System at a Tertiary Hospital: A Case Series Study. [PDF]

Neuropathology
Sina N, Heyn C, Ghorab Z, Keith J.
europepmc   +1 more source